# CIRRHOSIS

## 定義 
> (_Dig Dis_ 2016;34:374; _NEJM_ 2016;375:767; _J Hep_ 2016;64:717)

• 定義: **fibrosis and regenerative nodules** resulting from hepatocellular injury

• **Decompensated** = jaundice, variceal bleed, encephalopathy, ascites; worse prognosis

## 原因

• **Alcohol** (~60–70%) and other toxins (eg, arsenic)

• **Viral hepatitis** (~10%): chronic HBV, HCV, HDV infection

• **Autoimmune hepatitis:** ♀, ↑ IgG, ⊕ ANA, antismooth muscle Ab, anti-LKM-1, anti-LC1

• **Metabolic diseases** (~5%): hemochromatosis, Wilson disease, α1\-AT deficiency

• **Biliary tract diseases** (~5%): primary biliary cholangitis, secondary biliary cirrhosis (calculus, neoplasm, stricture, biliary atresia), primary sclerosing cholangitis

• **Vascular diseases:** Budd-Chiari syndrome, R-sided CHF, constrictive pericarditis, SOS

• **Nonalcoholic fatty liver dis. (NAFLD**, 10–15%) cause of most “cryptogenic cirrhosis”

• **Medications:** amiodarone, methotrexate, vitamin A, valproate acid, isoniazid

## 臨床表現

• Nonspecific sx (anorexia, fatigue) or jaundice, encephalopathy, ascites, variceal bleeding

Physical exam

• Liver: _initially_ enlarged, palpable (L lobe predom), firm; _eventually_ shrunken, nodular

• Signs of liver failure: jaundice (bili >2.5), spider angiomata & palmar erythema (↑ estra- diol), Dupuytren’s contractures, white nail lines (Muehrcke’s lines) & proximal nail beds (Terry’s nails), ↑ parotid & lacrimal glands, gynecomastia, testicular atrophy, asterixis, encephalopathy, fetor hepaticus, clubbing, hypertrophic osteoarthropathy

• Signs of portal hypertension: splenomegaly, ascites, dilated superficial abdominal veins (caput medusae), epigastric Cruveilhier-Baumgarten venous hum

## Laboratory studies

• LFTs: ↑ **bili**, ↑ **PT/INR** (poor correlation with bleeding; factor VIII 正常 b/c not synthesized by liver), ↓ **alb**, ± ↑ aminotransferases (AST > ALT if late) and ↑ Aϕ (variable)

• Hematologic tests: anemia (marrow suppress., hypersplenism, Fe ± folate defic.), neutro-penia (hypersplenism), thrombocytopenia (hypersplenism, ↓ Tpo production, EtOH tox)

• Chem: ↓ Na (↑ ADH due to ↓ EAV); ↑ Fe/TIBC, ↑ ferritin (released from hepatocytes)

• Lab indices predictive of cirrhosis: AST/plt >2; Lok index; Bonacini score (_JAMA_ 2012;307:832)

• Indirect markers of fibrosis: FibroTest/FibroSURE (HBV/HCV), FIB-4 index (NAFLD, HCV), NAFLD fibrosis score

## Workup 
> (_Lancet_ 2014;383:1749; _Am J Gastro_ 2017;112:18)

• Abd **U/S with Doppler:** liver size & echotexture, 排除 HCC, ascites, ✔ patency of vasculature

• Determine etiology: hepatitis serologies (HBsAg, anti-HBs, anti-HCV), autoimmune hepatitis studies (IgG, ANA, anti–smooth muscle Ab), Fe and Cu studies, α1\-AT, AMA

• Assess fibrosis: biomarkers (FibroSURE = panel of 5 markers validated in HCV, ↑ score predictive of fibrosis); elastography (U/S or MR-based; measurement of liver stiffness)

• Liver bx (gold standard): percutaneous or transjugular (consider if ascites or coagulopathy), used to confirm presence of cirrhosis and dx etiology

## Prognosis 
> ([www.mdcalc.com/child-pugh-score-cirrhosis-mortality](http://www.mdcalc.com/child-pugh-score-cirrhosis-mortality))

• **Modified Child-Turcotte-Pugh (CPS)** score based on ascites, enceph., & labs (bili, alb & INR; see Appendix). CPS A (5-6 病人): 1-y survival 100%, B (7–9): 80%; C (10–15): 45%.

• **MELD-Na** (**M**odel for **E**nd-Stage **L**iver **D**isease; _Gastro_ 2011;14:1952): used to stratify liver Tx list & predict 3-mo survival in cirrhosis and some acute forms of liver dis. Based on Cr, INR, total bili, Na. Calculator: [https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/](https://optn.transplant.hrsa.gov/resources/allocation-calculators/meld-calculator/).

If MELD <21, additional predictors of mortality include refractory ascites, ↑ HVPG & ↓ 生活品質.

MELD-Plus includes alb, chol, LOS, age, WBC (_PLOS One_ 2017;12:e0186301).

## Ascites 
> (see “Ascites” for diagnostic eval; _Liver Int_ 2016;36:S1:109; _Dig Dis_ 2017;35:402)

• Due to portal HTN (defined as hepatic venous pressure gradient \[HVPG\] >5 mmHg)

• Develops in 60% within 10 y; ~50% mortality at 5 y

• 治療: ↓ **Na intake** (1–2 g/d); restrict intake of free water if Na <125

**Diuretics:** goal diurese ~1 L/d. Use spironolactone ± furosemide in 5:2 ratio (eg, 100 & 40 mg daily); urine Na/K >1 implies effective natriuresis if Pt compliant with low-Na diet

Avoid NSAIDs in cirrhosis because interfere with diuretic action and are nephrotoxic

Albumin (40 g 2×/wk × 2 wk, then weekly × 16 wk) ↓ mortality 38% (_Lancet_ 2018;391:2417)

• **Refractory ascites:** seen in 5–10% of 病人; 2-y survival 25%

Diuretic-resistant on 2-g Na diet, minimal weight loss on maximal diuretic doses, or diuretic-induced complications (AKI, Na <125, ↑ K, encephalopathy)

Conflicting evid. for d/c’ing βB (_Hep_ 2016;63:1968; _J Hepatol_ 2016;64:574). Especially consider if SBP <90 or MAP ≤82 mmHg, serum Na <120 mEq/L, AKI, HRS, SBP, sepsis, severe alcoholic hepatitis, poor follow-up. If limited by HoTN, can add midodrine.

### Large-volume paracenteses 
> (LVP; >5 L fluid removal): give 6–8 g albumin per L fluid removed (above 5 L) as colloid replacement a/w ↓ risk of post-para circulatory dysfxn & possibly ↓ mortality (_Hep_ 2012;55:1172). Avoid LVP if SBP present because ↑ risk of AKI.

### Transjugular intrahepatic portosystemic shunt (TIPS)
> (_Gastro_ 2017;152:157)

↓ ascites in 75%; ↑ CrCl, ↑ enceph, survival benefit over LVP remains controversial

Contraindic: grade II enceph, CHF or pulm HTN, active infxn or biliary obstruction

Complications: bleeding, fistula; stent thrombosis (1-y patency with coated stents ~80%); infxn (“endotipsitis”); new or ↑ enceph in 20–30% (_Am J Gastro_ 2016;111:523), hemolysis

Consider for liver transplant if above fail

• **Hepatic hydrothorax:** 2° diaphragmatic defect; often unilateral, R > L, ± ascites

治療: avoid chest tube (↑ complications); Rx same as ascites (TIPS if refractory). Indwelling pleural catheter potential option if refractory (_Chest_ 2019;155:307)

Spontaneous _empyema_ can occur (even without SBP) → dx thoracentesis; Rx 抗生素

## Spontaneous bacterial peritonitis 
> (SBP; see “Ascites”; _Eur J Gastro Hep_ 2016;28:e10)

• Develops in ~20%; 20% mortality; risk factors: ascitic TP <1 g/dL, hx of SBP, current GIB

• Can 表現為 encephalopathy, abd pain, fever, _but often_ (_25%_) _asx;_ perform paracentesis in all hospitalized cirrhotics with ascites

• Micro: GNRs (_E. coli, Klebs_) > GPCs (_S. pneumo, enterococcus_) (see “Ascites”)

• Rx: 3rd\-gen. ceph _or_ amox/clav × 5 d. If uncomplicated (no enceph. or AKI) can use FQ but avoid in ↑ FQ resist. area. ↑ rate MDR organisms, incl. ESBL & carbapenemase. IV albumin 1.5 g/kg at time of dx & 1 g/kg on day 3 → ↑ survival (_NEJM_ 1999;341:403); con- sider using only if Cr >1 mg/dL, BUN >30 mg/dL or Tbili >4 mg/dL (_Gut_ 2007 56:597). If not improving, repeat paracentesis at 48 h: expect 25% ↓ in PMNs if Rx working.

• Indefinite Ppx if (1) h/o SBP or (2) ascitic TP <1.5 plus: Na ≤130 or Cr ≥1.2 or BUN ≥25 or \[CPS ≥9 + Tbili ≥3\] (_Am J Gastro_ 2009;4:993) → cipro 500 mg qd or Bactrim DS qd. Short-term Ppx: CTX 1 g IV × 7d if GIB (Δ to cipro 500 bid/Bactrim DS bid when eating).

## Gastroesophageal varices ± UGIB 
> (see also “GIB”; _Hepatology_ 2017;65:310)

• Presence of varices correlates with severity of liver dis (40% of Child A 病人 → 85% Child C)

• ↑ varix size, Child B/C, & red wale marks assoc with ↑ risk of bleeding

• UGIB 1° prevention: screen at time of dx with EGD; data best for 病人 with med-large varices

**nonselective β-blockers:** ~50% ↓ risk of bleeding & ↓ mortality if med-large varices. Nadolol, propranolol, or carvedilol; latter ↓ MAP & HVPG more than propranolol; delays progression of varices (_Gut_ 2017;66:1838); may use in 病人 with HTN. Titrate to max tolerated dose; EGD not req. to document improvement. Hold for criteria listed above.

### endoscopic variceal ligation (EVL): 
> superior to βB in ↓ risk of 1st bleed but no diff in mortality (_Ann Hep_ 2012;11:369); risk of serious complications (esoph perf, ulcers). Repeat q1–2wk until varices gone, with f/u EGD at 3 mo then q6–12mo.

βB vs. EVL: choice based on Pt/physician preference, βB often 1st (_Hepatology_ 2017;65:310); using both βB and EVL for primary ppx currently not recommended

• 2° prevention: for all 病人 after 1st bleed, given ~50% risk of rebleed & ~30% mortality βB + EVL > either alone; TIPS if refractory, or consider in Child B/C within 72 h of admission for EV bleed (↓ rebleeding, ↑ enceph., ∅ Δ mort.) (_Hepatology_ 2016;63:581)

## Hepatic encephalopathy 
> (HE) (_NEJM_ 2016;375:1660)

• Pathogenesis: failure of liver to detoxify NH3 + other substances (eg, ADMA; _J Hepatol_ 2013;58:38) that cause cerebral edema, ↓ O2 consumption, ↑ ROS → brain dysfxn

• Precipitants: bleeding, infxn, med nonadherence, ↓ K, ↓ Na, dehydration, hypoxia, portosystemic shunt (eg, TIPS), meds (eg, sedatives), acute insult to liver (eg, PVT)

• Stages: see section in “Acute Liver Failure”

• Dx: NH3 levels have poor Se for dx & monitoring Rx; remains a _臨床dx_

• Rx_:_ identify/correct precipitants; **lactulose** (acidification of colon: NH3 → NH4+) with goal 2–4 stools/d (PEG may be more effective; _JAMA IM_ 2014;174:1727); alternatively, **rifaximin** 550 mg bid (↓ gut bacteria → ↓ NH3 prod; ? benefit to adding rifaximin to lactulose; _Am J Gastro_ 2013;108:1458); adding albumin may speed resolution & ↓ mort. (_J Gastro Hep_ 2017;32:1234)

• 2° prevention: lactulose or rifaximin 550 mg bid (_Aliment Pharmacol Ther_ 2015;41:39)

## Hepatorenal syndrome (HRS) 
> (_Am J Kidney Dis_ 2016;67:318; _Gastro_ 2016;150:1525)

• Pathophys: splanchnic vasodilation and renal vasoconstriction with ↓ renal blood flow

• Criteria: (1) cirrhosis with ascites; (2) **acute kidney injury** (serum Cr ↑ ≥0.3 mg/dL within 48 h or ≥50% ↑ in serum Cr from baseline; _Gut_ 2015;64:531); (3) ∅ improvement in Cr after d/c diuretic & volume expansion (1 g/kg/d of albumin × 2 d); (4) ∅ shock (prerenal azotemia/ATN); (5) ∅ nephrotoxic meds; (6) ∅ intrinsic kidney disease

**AKI-HRS:** development in <2 wk; usually occurs in severe liver failure, often following precipitating event (see later); median survival 2 wk

**CKD-HRS:** more indolent, median survival 6 mo; liver failure present < than in AKI-HRS

• Precipitants: GIB, overdiuresis, infection, serial LVP, drugs (aminoglycosides, NSAIDs)

• Rx: _if critically ill_ → vasopressor (eg, norepinephrine or vasopressin) + albumin (1 g/kg, max 100 g, bolus daily) to ↑ MAP 10 mmHg. _If not critically ill_ → octreotide (100–200 mcg SC tid) + midodrine (max 15 mg PO tid) + 1 g/kg (max 100 g) albumin on day of presentation followed by 20–60 g albumin qd to ↑ MAP. Serelaxin under study (_PLoS Med_ 2017;14:e1002248). May need dialysis or TIPS as bridge to liver transplant.

## Hepatocellular carcinoma 
> (HCC; qv in Heme-Onc) (_Gastro_ 2016;149:1226 & 150:835)

• ↑‘d risk with cirrhosis of any type but esp. with viral (risk of HCC ~3–8%/y), HFE, PBC, ?α1-AT. ↑‘d by concomitant EtOH (_J Hepatol_ 2016;65:543).

• Clinical: asx vs. hepatic decompensation (eg, ascites, HE), PVT with tumor thrombus

• Dx: screen cirrhotics q6mo with U/S ± AFP, though many ctrs choose dual-phase CT/MRI

• Rx: see “HCC” in Heme-Onc

## Other complications

• **Hepatopulmonary syndrome** (HPS) (_Dig Dis Sci_ 2015;60:1914)

異常 gas exchange (A-a gradient ≥15 or PaO2 <80) caused by intrapulmonary vascular dilatations leading to intrapulmonary shunting

S/S: platypnea-orthodeoxia, clubbing, cyanosis

Dx with contrast echo showing “late” A-V shunting (contrast in LA 3–6 cycles after RA)

Rx: O2; potential embolization if large vessel on CT, ? TIPS, liver tx only definitive Rx

• **Portopulmonary hypertension** (POPH) (_Expert Rev Gastro Hepatol_ 2015;9:983)

Pulm HTN in Pt with portal HTN without other cause. ESLD→ ↑ endothelin→ pulm vasoconst.

Rx with same therapies as for idiopathic PAH, incl prostacyclin analogs, endothelin receptor antagonists, sildenafil; liver transplant is often curative

• **Cirrhotic cardiomyopathy:** ↓ inotropic & chronotropic response, ↓ systolic & diastolic fxn, ↑ QT, hyperkinetic circulation; ↑ troponin, BNP (_World J Gastro_ 2017;21:11503)

• **Infxns:** unless already immune, vaccinate for HAV, HBV, PCV13 & PPSV23; flu yearly. Cellulitis in ~20% of 病人 hospitalized with cirrhosis, often in abd wall or LE a/w skin edema.

• Endocrine: diabetes (15–30%), ↑ frequency of adrenal insuffic. (_Dig Dis Sci_ 2017;62:1067)

• Coagulopathy: balanced defects with ↓ synth of coag factors, hyperfibrinolysis, ↓ plt balanced by ↓ synthesis anticoag factors (protein C/S), defic. of profibrinolytic factors, ↑ levels of vWF. No support for routine administration of FFP, plt, cryo unless in DIC.

• Nutrition: monitor and supplement fat-soluble vitamins, zinc

• Meds: acetaminophen can be used up to 2 g/d; avoid ASA/NSAIDs; aminoglycosides contraindicated; oral hypoglycemics if compensated but insulin if decompensated

## Liver transplantation

• Undertake evaluation when MELD ≥15. Exception points added if HCC as above, HPS

• Indic: recurrent/severe enceph, refractory ascites, recurrent variceal bleeding, HRS, HPS, PPH, HCC (if no single lesion is >5 cm _or_ ≤3 lesions with largest ≤3 cm), ALF

• Contraindic: inadequate social support, active substance abuse (EtOH within 6 mo), sepsis, advanced cardiopulm dis., extrahepatic Ca, cholangio Ca, hemangiosarcoma, persistent noncompliance, AIDS, ALF with sustained ICP >50 mmHg or CPP <40 mmHg

• Survival: 1-y up to 90%, 5-y up to 80%, though lower with HCV; autoimmune liver disease, such as AIH/PBC/PSC may recur in 10–30% (or more) of allografts

# OTHER 原因 OF CIRRHOSIS

## Hemochromatosis & iron overload syndromes 
> (_Lancet_ 2016;388:706)

• Recessive disorder of iron sensing or transport leading to tissue **iron deposition**

• **HFE** mutations (85% of cases): typically C282Y homozyg. (~0.5% of N. Europeans), rarely C282Y/H63D compound heterozyg. C282Y homozygotes: 28% of ♂ & 1% of ♀ develop sx (delayed since menses ↓ Fe load). C282Y/H63D: only 1.5% manifest dis.

• Non-HFE mutations: hemojuvelin, hepcidin, transferrin receptor 2, & ferroportin

• 2° causes of iron overload: iron-loading anemias (eg, thalassemia major, sideroblastic anemia, aplastic anemia), parenteral iron-overload (RBC transfusions, long-term HD), chronic liver disease (due to ETOH, HBV, HCV, NASH, etc.), dietary iron overload

• Sx: fatigue & arthralgias, loss of libido in ♂. In _advanced disease_ (rare): bronze skin (melanin + iron), hypogonadism (esp. in juvenile onset), DM, arthropathy (MCP), CHF, infxns (↑ risk _Vibrio_, _Listeria_, _Yersinia_), cirrhosis (↑ risk if EtOH/fatty liver disease; 15% risk of HCC). Disease also a/w ALS (H63D homozygotes) & porphyria.

• Dx: iron sat >45% (iron/TIBC × 100%); ↑ ferritin (acute phase reactant, so poor Sp; often 正常 in young 病人). If ↑ iron sat. → ✔ HFE to confirm dx, imaging by MRI (black liver). If HFE ⊕ & ferritin >1000 ng/mL or ↑ LFTs → liver bx for quant Fe index & to stage fibrosis

• 治療: phlebotomy (250 mL = 1 unit, ~250 mg of Fe) qwk until Fe sat <50% & ferritin 50–100 µg/L, then q3–4mo; PPI ↓ intestinal Fe absorption & may ↓ need for phlebotomy; avoid vit C & uncooked seafood; deferoxamine if phleb. contraindic.; genetic counseling

## Wilson disease 
> (_World J Hepatol_ 2015;7:2859)

• Recessive disorder of copper transport (mutation in _ATP7B_) → **copper overload;** primarily affects liver, but also other tissues (brain, eye)

• 流行病學: 1 in ~30,000, but true allele frequency may be higher due to underdiagnosis; age of presentation generally ranges from 3 to 55 y

• Extrahepatic signs and symptoms: neuro ψ disease, parkinsonism & movement disorder (hepatolenticular disease), Kayser-Fleischer rings (⊕ in 99% with neuro ψ but in <50% with hepatic disease), Coombs ⊖ hemolytic anemia, renal disease

• Dx: ↑ 24-h urine Cu, ↓ serum ceruloplasmin (Se 90%), rarely penicillamine challenge with ↑ urine Cu excretion, liver bx with hepatic Cu content. In _acute liver failure_, Aϕ/bili <4 + AST/ALT >2.2 better Se & Sp than urine Cu or ceruloplasmin (_Hepatology_ 2008;4:1167).

• 治療: **chelation** with D\-penicillamine (supplement B6 as D\-pen inactivates); alternative is trientine (↓ toxicity with ≈ efficacy, but $$)
**Zinc:** ↓ intestinal Cu transport & can help delay disease; best used in conjunction with chelation (must give 4–5 h apart from chelators). Elim. Cu-rich foods. Transplant for ALF or for chronic dis. unresponsive to Rx

## α1-antitrypsin deficiency 
> (α1\-AT) (_J Hepatol_ 2016;65:413)

• 異常 α1\-AT → polymerization in liver (cirrhosis) & uninhibited protease activity in lung (emphysema). Affects 1/3000 of European ancestry. Varied presentations: neonatal hepatitis; cholestatic jaundice in children; ↑ AST/ALT or cirrhosis in children/adults.

• Extrahepatic disease includes: emphysema, necrotizing panniculitis, ANCA vasculitis

• Dx: serum α1\-AT level (acute phase reactant), level <50% of 正常 typically diagnostic;

gold standard = phenotyping of protease inhibitor (Pi). Alleles most a/w hepatic dis.: Z (63% of ZZ adults have chronic liver dis. and liver fibrosis may be present in 35% of ZZ individuals without overt liver disease) & M (malton) (_J Hepatol_ 2018;69(6):1357). Liver bx shows characteristic PAS ⊕ cytoplasmic inclusion bodies.

• 治療: standard Rx for cirrhosis/chronic liver dis., including liver transplantation

## Primary biliary cholangitis 
> (PBC) (_Lancet_ 2015;386:1565)

• Autoimmune destruction of _intrahepatic_ bile ducts (previously “primary biliary cirrhosis”)

• Epi: ♀ 40–60 y; a/w Sjögren’s, Raynaud’s, scleroderma, celiac & thyroid disease; may be triggered by certain infxns or toxins; a/w X monosomy, variants in IL12α & IL12R genes

• Sx (late): fatigue/sleep disturbance, pruritus, steatorrhea, xanthelasma, jaundice, cirrhosis

• Ddx: PSC, AIH, hepatic sarcoidosis, meds, idiopathic adult ductopenia, biliary stricture/Ca

• Dx: ↑ Aϕ, ↑ bili, ↑ IgM, ↑ chol, ⊕ antimitochondrial Ab (AMA) in 95%. If ⊕ AMA, liver bx not needed due to high Se & Sp. 0.5% gen pop ⊕ AMA & 正常 LFTs → 10% develop PBC at 6 y. If AMA ⊖, liver bx (Pts often ⊕ ANA, smooth muscle Ab; same prognosis as ⊕ AMA).

• Rx: **ursodeoxycholic acid** (13–15 mg/kg/d) regardless of stage (30% of 病人 untreated!)

~25% complete response, ↑ survival & ↓ histologic change & complications (eg, varices). Biochemical response predicts 臨床outcomes (_Clin Gastro Hep_ 2018;16:1342).

Bezafibrate (not available in U.S. but fenofibrate similar) appears to be effective 2nd\-line agent in combo with UDCA if inadequate response to UDCA (_NEJM_ 2018;378:2171)

Obeticholic acid (5 → 10 mg qd, except CPS B/C: 5 mg/wk → 10 mg twice weekly) ↓ Aφ, but no fat-soluble vitamins; screen/Rx osteoporosis fibrosis (_NEJM_ 2016;375:631)

Pruritus: cholestyramine (give 2–4 h after UDCA); if refractory sx: naltrexone, rifampin

Fat-soluble vitamins; screen/Rx osteoporosis (risk independent of vit D deficiency)

If ESLD: liver tx; ~20% recur but no impact on long-term survival

## Primary sclerosing cholangitis (PSC) 
> (_NEJM_ 2016;375:1161; _Lancet_ 2018;391:2547)

• Diffuse inflammation of _intrahepatic and extrahepatic_ bile ducts leading to fibrosis & stricturing of biliary system. A/w HLA-B8 and -DR3 or -DR4, frequent ⊕ autoantibodies.

• Epi: ♂ > ♀ (20–50 y) ~70% 病人 with PSC have IBD (usually UC); only 1–4% with UC have PSC. ⊕ prognostic factors: ♂, absence of IBD, small duct PSC (_Gastro_ 2017;152:1829).

• Clinical: fatigue, pruritus, jaundice, fevers, RUQ pain, concomitant IBD, ESLD

• Ddx: extrahepatic obstruction, PBC, may also have overlap with AIH and similar presentation to IgG4 autoimmune cholangitis (steroid responsive) (_J Gastro_ 2016;51:295)

• Dx: MRCP ± ERCP → _multifocal beaded bile duct strictures_, but may miss dx if confined to small intrahepatic ducts (~2% “small duct PSC”:? different disease). Aφ predicts survival. Liver bx may show “onion-skin” fibrosis around bile ducts but not necessary for dx.

• 治療: supportive care, fat-soluble vitamins; no meds have improved survival Ursodeoxycholic acid may ↓ colon Ca risk in 病人 with UC & improve LFTs in 病人 without UC

Dominant stricture: endoscopic dilation, short-term stenting or surgical resection

Cholangiocarcinoma (20%): ? biannual surveillance with MRCP/RUQ U/S and CA19-9

Liver transplantation: ~30% recurrence, though if UC, colectomy may ↓ recurrence
